InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,614.63
(
-0.20%
)
US TECH 100
18,866.00
(
-0.78%
)
Dow Jones
41,483.44
(
0.22%
)
Brent Oil
72.17
(
1.09%
)
Bitcoin
57,855.88
(
-2.23%
)
Post# of 253127
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120438
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 128876

Friday, 10/21/2011 5:58:24 PM

Friday, October 21, 2011 5:58:24 PM

Post# of 253127
Based on MNTA’s limited expedited discovery, MNTA told the Court yesterday that Amphastar does infringe MNTA’s ‘466 patent, which covers the 1,6 anhydro structural component of Lovenox that the FDA said is a requirement for showing sameness to branded Lovenox.

Based on the same expedited discovery, MNTA also told the Court that Amphastar does not infringe on MNTA’s ‘886 patent, so you no longer need to worry about the claims in that patent.

Source: MNTA’s webcast at today’s BioCentury conference (http://phx.corporate-ir.net/phoenix.zhtml?c=136783&p=conferenceAgenda&id=4170520&day=1 )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up